Loading…

Rat activin-βE mRNA expression during development and in acute and chronic liver injury

Activin-βE mRNA expression was investigated in male and female rats using gel-based and quantitative RT-PCR, in fetal and post-natal liver during development and in a variety of tissues from 200 gm adult animals. Activin-βE expression was also assessed in rat liver after partial hepatectomy, and aft...

Full description

Saved in:
Bibliographic Details
Published in:Journal of molecular and genetic medicine 2006-04, Vol.2 (1), p.93-100
Main Authors: Gold, Elspeth J, Monaghan, Marcel A, Fleming, Jean S
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 100
container_issue 1
container_start_page 93
container_title Journal of molecular and genetic medicine
container_volume 2
creator Gold, Elspeth J
Monaghan, Marcel A
Fleming, Jean S
description Activin-βE mRNA expression was investigated in male and female rats using gel-based and quantitative RT-PCR, in fetal and post-natal liver during development and in a variety of tissues from 200 gm adult animals. Activin-βE expression was also assessed in rat liver after partial hepatectomy, and after repeated toxic insult. Male Sprague Dawley rats were subjected to partial hepatectomy or sham operations. Samples were collected from the caudate liver lobe during regeneration, from 12 to 240 hr after surgery. Three groups of 5 male rats were treated with CCl 4 for 0 (control), 5 or 10 weeks, to induce liver fibrosis and cirrhosis. Activin-βE mRNA was predominantly expressed in liver, with much lower amounts of mRNA observed in pituitary, adrenal gland and spleen, in both males and females. Low activin-βE expression was observed in liver at fetal day 16, with higher levels seen between post-natal days 3 and 35 and a further increase noted by day 47, in both males and females. Liver activin-βE mRNA concentrations did not change from control values 12-72 hr after PHx, but significantly increased over six fold, 168 hr post-hepatectomy, when liver mass was restored. Activin-βE mRNA was up-regulated after 5 weeks of CCl 4 treatment, but not after 10 weeks. The changes in activin-βE mRNA concentrations after liver insult did not always parallel those reported for the activin-βC subunit, suggesting activin-βE may have an independent role in liver under certain conditions.
format article
fullrecord <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2702058</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_2702058</sourcerecordid><originalsourceid>FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_27020583</originalsourceid><addsrcrecordid>eNqljEsKwjAURYMgWj97yAYK6V8ngkjFkYPiwFmI7bM-aZOStMFuy4W4Jos4cezocjn3nhFxvCRMXLaK_SmZGXNnLPR8Fk_I1FtHccRY4JBzJloq8hYtSvf1TGmdHbcUHo0GY1BJWnQaZUkLsFCppgY5zGVBUQ6vroVPyW9aScxphRb0gO6d7hdkfBWVgeU352SzT0-7g9t0lxqKfBBpUfFGYy10z5VA_ksk3nipLPcT5rNoFfwteAOISlq8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Rat activin-βE mRNA expression during development and in acute and chronic liver injury</title><source>PubMed (Medline)</source><creator>Gold, Elspeth J ; Monaghan, Marcel A ; Fleming, Jean S</creator><creatorcontrib>Gold, Elspeth J ; Monaghan, Marcel A ; Fleming, Jean S</creatorcontrib><description>Activin-βE mRNA expression was investigated in male and female rats using gel-based and quantitative RT-PCR, in fetal and post-natal liver during development and in a variety of tissues from 200 gm adult animals. Activin-βE expression was also assessed in rat liver after partial hepatectomy, and after repeated toxic insult. Male Sprague Dawley rats were subjected to partial hepatectomy or sham operations. Samples were collected from the caudate liver lobe during regeneration, from 12 to 240 hr after surgery. Three groups of 5 male rats were treated with CCl 4 for 0 (control), 5 or 10 weeks, to induce liver fibrosis and cirrhosis. Activin-βE mRNA was predominantly expressed in liver, with much lower amounts of mRNA observed in pituitary, adrenal gland and spleen, in both males and females. Low activin-βE expression was observed in liver at fetal day 16, with higher levels seen between post-natal days 3 and 35 and a further increase noted by day 47, in both males and females. Liver activin-βE mRNA concentrations did not change from control values 12-72 hr after PHx, but significantly increased over six fold, 168 hr post-hepatectomy, when liver mass was restored. Activin-βE mRNA was up-regulated after 5 weeks of CCl 4 treatment, but not after 10 weeks. The changes in activin-βE mRNA concentrations after liver insult did not always parallel those reported for the activin-βC subunit, suggesting activin-βE may have an independent role in liver under certain conditions.</description><identifier>EISSN: 1747-0862</identifier><identifier>PMID: 19565003</identifier><language>eng</language><publisher>Library Publishing Media</publisher><ispartof>Journal of molecular and genetic medicine, 2006-04, Vol.2 (1), p.93-100</ispartof><rights>Copyright Elspeth Gold et al 2006</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702058/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702058/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,53791,53793</link.rule.ids></links><search><creatorcontrib>Gold, Elspeth J</creatorcontrib><creatorcontrib>Monaghan, Marcel A</creatorcontrib><creatorcontrib>Fleming, Jean S</creatorcontrib><title>Rat activin-βE mRNA expression during development and in acute and chronic liver injury</title><title>Journal of molecular and genetic medicine</title><description>Activin-βE mRNA expression was investigated in male and female rats using gel-based and quantitative RT-PCR, in fetal and post-natal liver during development and in a variety of tissues from 200 gm adult animals. Activin-βE expression was also assessed in rat liver after partial hepatectomy, and after repeated toxic insult. Male Sprague Dawley rats were subjected to partial hepatectomy or sham operations. Samples were collected from the caudate liver lobe during regeneration, from 12 to 240 hr after surgery. Three groups of 5 male rats were treated with CCl 4 for 0 (control), 5 or 10 weeks, to induce liver fibrosis and cirrhosis. Activin-βE mRNA was predominantly expressed in liver, with much lower amounts of mRNA observed in pituitary, adrenal gland and spleen, in both males and females. Low activin-βE expression was observed in liver at fetal day 16, with higher levels seen between post-natal days 3 and 35 and a further increase noted by day 47, in both males and females. Liver activin-βE mRNA concentrations did not change from control values 12-72 hr after PHx, but significantly increased over six fold, 168 hr post-hepatectomy, when liver mass was restored. Activin-βE mRNA was up-regulated after 5 weeks of CCl 4 treatment, but not after 10 weeks. The changes in activin-βE mRNA concentrations after liver insult did not always parallel those reported for the activin-βC subunit, suggesting activin-βE may have an independent role in liver under certain conditions.</description><issn>1747-0862</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqljEsKwjAURYMgWj97yAYK6V8ngkjFkYPiwFmI7bM-aZOStMFuy4W4Jos4cezocjn3nhFxvCRMXLaK_SmZGXNnLPR8Fk_I1FtHccRY4JBzJloq8hYtSvf1TGmdHbcUHo0GY1BJWnQaZUkLsFCppgY5zGVBUQ6vroVPyW9aScxphRb0gO6d7hdkfBWVgeU352SzT0-7g9t0lxqKfBBpUfFGYy10z5VA_ksk3nipLPcT5rNoFfwteAOISlq8</recordid><startdate>20060412</startdate><enddate>20060412</enddate><creator>Gold, Elspeth J</creator><creator>Monaghan, Marcel A</creator><creator>Fleming, Jean S</creator><general>Library Publishing Media</general><scope>5PM</scope></search><sort><creationdate>20060412</creationdate><title>Rat activin-βE mRNA expression during development and in acute and chronic liver injury</title><author>Gold, Elspeth J ; Monaghan, Marcel A ; Fleming, Jean S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_27020583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Gold, Elspeth J</creatorcontrib><creatorcontrib>Monaghan, Marcel A</creatorcontrib><creatorcontrib>Fleming, Jean S</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of molecular and genetic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gold, Elspeth J</au><au>Monaghan, Marcel A</au><au>Fleming, Jean S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rat activin-βE mRNA expression during development and in acute and chronic liver injury</atitle><jtitle>Journal of molecular and genetic medicine</jtitle><date>2006-04-12</date><risdate>2006</risdate><volume>2</volume><issue>1</issue><spage>93</spage><epage>100</epage><pages>93-100</pages><eissn>1747-0862</eissn><abstract>Activin-βE mRNA expression was investigated in male and female rats using gel-based and quantitative RT-PCR, in fetal and post-natal liver during development and in a variety of tissues from 200 gm adult animals. Activin-βE expression was also assessed in rat liver after partial hepatectomy, and after repeated toxic insult. Male Sprague Dawley rats were subjected to partial hepatectomy or sham operations. Samples were collected from the caudate liver lobe during regeneration, from 12 to 240 hr after surgery. Three groups of 5 male rats were treated with CCl 4 for 0 (control), 5 or 10 weeks, to induce liver fibrosis and cirrhosis. Activin-βE mRNA was predominantly expressed in liver, with much lower amounts of mRNA observed in pituitary, adrenal gland and spleen, in both males and females. Low activin-βE expression was observed in liver at fetal day 16, with higher levels seen between post-natal days 3 and 35 and a further increase noted by day 47, in both males and females. Liver activin-βE mRNA concentrations did not change from control values 12-72 hr after PHx, but significantly increased over six fold, 168 hr post-hepatectomy, when liver mass was restored. Activin-βE mRNA was up-regulated after 5 weeks of CCl 4 treatment, but not after 10 weeks. The changes in activin-βE mRNA concentrations after liver insult did not always parallel those reported for the activin-βC subunit, suggesting activin-βE may have an independent role in liver under certain conditions.</abstract><pub>Library Publishing Media</pub><pmid>19565003</pmid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 1747-0862
ispartof Journal of molecular and genetic medicine, 2006-04, Vol.2 (1), p.93-100
issn 1747-0862
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2702058
source PubMed (Medline)
title Rat activin-βE mRNA expression during development and in acute and chronic liver injury
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T11%3A01%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rat%20activin-%CE%B2E%20mRNA%20expression%20during%20development%20and%20in%20acute%20and%20chronic%20liver%20injury&rft.jtitle=Journal%20of%20molecular%20and%20genetic%20medicine&rft.au=Gold,%20Elspeth%20J&rft.date=2006-04-12&rft.volume=2&rft.issue=1&rft.spage=93&rft.epage=100&rft.pages=93-100&rft.eissn=1747-0862&rft_id=info:doi/&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_2702058%3C/pubmedcentral%3E%3Cgrp_id%3Ecdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_27020583%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/19565003&rfr_iscdi=true